Close Menu

NEW YORK ─ Marlborough, Massachusetts-based Hologic announced after the close of the market on Tuesday that it will acquire molecular diagnostics firm Biotheranostics for approximately $230 million.

San Diego-based Biotheranostics develops and provides diagnostic, prognostic, and predictive tests that support physicians in the treatment of cancer patients.

The company offers testing services through a CLIA-certified, CAP-accredited laboratory that is directly licensed or otherwise authorized to perform testing in all 50 US states, Hologic said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.